Corpus overview


Overview

MeSH Disease

Human Phenotype

Abdominal pain (11)

Fever (8)

Cough (7)

Diarrhea (7)

Fatigue (6)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 11
    records per page




    Unusual Presentation of Kawasaki Disease MESHD with Multisystem Inflammation MESHD and Antibodies SERO Against Severe Acute Respiratory Syndrome MESHD Coronavirus 2: A Case Report

    Authors: Haena Kim; Jung Yeon Shim; Jae-Hoon Ko; Aram Yang; Jae Won Shim; Deok Soo Kim; Hye Lim Jung; Ji Hee Kwak; In Suk Sol

    doi:10.21203/rs.3.rs-41276/v1 Date: 2020-07-12 Source: ResearchSquare

    Background: Since mid-April 2020, cases of multisystem inflammatory syndrome MESHD in children TRANS (MIS-C) associated with coronavirus disease MESHD (COVID-19) that mimic Kawasaki disease MESHD ( KD MESHD) have been reported in Europe and North America. However, no cases have been in East Asia, where KD MESHD is more prevalent.Case presentation: A previously healthy 11-year-old boy was admitted with a 4-day history of fever HP fever MESHD and abdominal pain HP abdominal pain MESHD. He had no contact history to any patient with COVID-19. Blood SERO acute inflammatory markers were highly elevated. He was treated with antibiotics for suspected bacterial enteritis MESHD, but he suddenly developed hypotension HP hypotension MESHD. Inotropics and intravenous immunoglobulin were administered to manage septic shock MESHD shock HP. On hospitalization day 6, he developed signs and symptoms of KD MESHD (conjunctival injection, strawberry tongue HP, cracked lip MESHD, and coronary artery dilatation MESHD dilatation HP) in addition to pleural/pericardial effusion MESHD pericardial effusion HP and mesenteric lymphadenitis HP lymphadenitis MESHD. The results of microbiologic tests, including reverse-transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), were negative. Fluorescent immunoassay SERO and enzyme-linked immunosorbent assay SERO revealed abundant IgG antibodies SERO against SARS-CoV-2 in his serum SERO, but no IgM antibodies SERO. He was discharged successfully on day 13.Conclusion: MIS-C may occur in children TRANS with a previously asymptomatic TRANS COVID-19 infection MESHD. A high index of suspicion is required for this novel syndrome in unusual cases of KD MESHD or KD shock syndrome MESHD shock HP syndrome with multisystem inflammation MESHD, even when there is no clear history of contact or symptoms of COVID-19.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients):  fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from a meta-analysis across 13 countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v2 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians. Objective: The objective was to identify symptoms and their frequencies of COVID-19 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included in meta-analysis. Data abstraction and analysis: PRISMA guidelines, used for data abstraction and a table was generated by feeding it with numbers and proportions of each symptom described. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals were calculated.Results: Selected 14 studies, either cross-sectional or cohort studies are analyzed. There were 2,660 confirmed cases TRANS of COVID-19. The majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms identified from the meta-analysis and additional 7 symptoms were identified from reference searching. The most common symptoms were ( prevalence SERO >50%): fever HP fever MESHD (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP anosmia MESHD, sneezing HP, ocular pain HP ocular pain MESHD, fatigue HP fatigue MESHD, sputum production, arthralgia HP arthralgia MESHD, tachypnea HP tachypnea MESHD, palpitation HP, headache HP headache MESHD, chest tightness HP chest tightness MESHD, shortness of breath MESHD, chills HP, myalgia HP myalgia MESHD, sore throat, anorexia HP anorexia MESHD, weakness MESHD, diarrhea HP diarrhea MESHD, rhinorrhea HP rhinorrhea MESHD, dizziness MESHD, nausea HP nausea MESHD, altered level of consciousness, vomiting HP vomiting MESHD and abdominal pain HP abdominal pain MESHD. Rare symptoms (<5%): tonsil swelling MESHD, haemoptysis, conjunctival injection, lymphadenopathy HP lymphadenopathy MESHD and rash MESHD. Conclusion and implications of key findings: We found (25/32, from meta-analysis) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified is different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.  

    Alarming Symptoms Leading To Severe COVID-19 Pneumonia HP: A Meta-Analysis

    Authors: Weiping Ji; Jing Zhang; Gautam Bishnu; Xudong Du; Xinxin Chen; Hui Xu; Xiaoling Guo; Zhenzhai Cai; Jun Zhang; Xian Shen

    doi:10.21203/rs.3.rs-35449/v1 Date: 2020-06-14 Source: ResearchSquare

    Background: To identify alarming symptoms that could potentially lead to severe form of COVID-19 pneumonia HP pneumonia MESHD (i.e. novel coronavirus pneumonia MESHD pneumonia HP: NCP), a disease that is now having pandemic spread.Methods: Articles from PubMed, Embase, Cochrane database and Google up to 24 February 2020 were systematically reviewed. 18 publications that had documented cases of COVID-19 pneumonia HP pneumonia MESHD were identified. The relevant data were extracted, systematically reviewed and further evaluated using meta-analysis. We define severe COVID-19 pneumonia HP pneumonia MESHD as the disease status that requires admission to the intensive care unit (ICU) and respiratory/circulatory support, which is in align with the guideline from the World Health Organization (WHO).Results: 14 studies including 1,424 patients were considered eligible and analyzed. Symptoms such as fever HP fever MESHD (89.2%), cough HP (67.2%), fatigue HP fatigue MESHD (43.6%) were quite common; but dizziness MESHD, hemoptysis HP, abdominal pain HP abdominal pain MESHD and conjunctival congestion/ conjunctivitis HP conjunctivitis MESHD were relatively rare. The incidence of dyspnea HP dyspnea MESHD was significantly higher in patients with severe than non-severe COVID-19 pneumonia HP pneumonia MESHD (42.7% vs.16.3%, p<0.0001). Similarly, fever HP fever MESHD and diarrhea HP diarrhea MESHD were also drastically more common in patients with severe form (p=0.0374 and 0.0267). Further meta-analysis using three high-quality China-based studies confirmed such findings and showed that dyspnea HP dyspnea MESHD, fever HP fever MESHD and diarrhea HP diarrhea MESHD were 3.53 (OR: 3.53, 95%CI: 1.95-6.38), 1.70 (OR: 1.70, 95%CI: 1.01-2.87), and 1.80 (OR: 1.80, 95%CI: 1.06-3.03) folds higher respectively in patients with severe COVID-19 pneumonia HP pneumonia MESHD.Conclusion: Dyspnea HP Dyspnea MESHD, fever HP and diarrhea HP diarrhea MESHD are significantly more prevalent in patients with severe COVID-19 pneumonia HP pneumonia MESHD, suggesting they are alarming symptoms that warrant close attention and timely management.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-30405/v1 Date: 2020-05-19 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected MESHD patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever HP fever MESHD in 13 (65%) patients, cough HP in 9 (45%), headache HP headache MESHD in 3 (15%), fatigue HP fatigue MESHD in 6 (30%), diarrhea HP diarrhea MESHD in 3 (15%), and abdominal pain HP abdominal pain MESHD in 2 (10%). Six patients (30%) developed shortness of breath MESHD upon admission. The median time from exposure to onset of illness was6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency. The dynamic changes in lymphocyte levels can predict disease status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    Covid-19 infection MESHD without respiratory symptoms: case report of diagnosing a 14 year-old patient with acute abdomen 

    Authors: Ladan Goshayeshi; Nasrin Milani; Robert Bergqueist; Sayyed Majid Sadrzadeh; Farnood Rajabzadeh; Benyamin Hoseini

    doi:10.21203/rs.3.rs-27389/v1 Date: 2020-05-07 Source: ResearchSquare

    Background. C oronavirus Disease MESHD2019 (Covid-19) is expanding worldwide. Although it seems to be a purely r espiratory disease, MESHD occasional reports of lesions in other organs have been published. We report here an asymptomatic TRANS child TRANS Covid-19 patient with the main symptom of abdominal HP bdominal pain MESHD pain HP distension and without any respiratory symptoms.Case presentation. A 14 year-old male TRANS patient without respiratory involvement but with main complaints of fever HP ever, MESHD m alaise, MESHD anorexia HP norexia, MESHD and severe abdominal pain HP bdominal pain MESHDwas admitted to a hospital in Mashhad, Iran. Following general anaesthesia, laparotomy revealed distension of the small intestine and an adhesive ileo-caecal band that had produced ileum herniation without free fluid in the abdomen. The band was surgically severed and the patient referred to the recovery room.  Because of pulse rate of 36-40 per min and respiratory rate of 140 and a saturated O2 of 86%, the patient was referred to the intensive care unit. Chest X-ray and high-resolution computed tomography of the lungs showed bilateral, diffuse, peripheral dense areas of ground-glass appearance. A nasopharyngeal swab for Covid-19 diagnosis, ordered due to lymphopenia HP ymphopenia MESHDtogether with these diffuse lung infiltrations, showed a positive result. This led to drug treatment with lopinavir/ritonavir, hydroxychloroquine, ribavirin/oseltamivir and meropenem. The patient was febrile and developed tachycardia HP achycardia MESHDon the third day accompanied with a respiratory rate of 44/min. At this point, tracheal intubation was done but the patient died after 3 hours due to cardiac arrest HP ardiac arrest. MESHDConclusions. The case report brings forth the hypothesis that the gastrointestinal manifestation may be untypical symptoms of Covid-19 i nfection, MESHD and highlights the importance for the diagnosis to be based on combined laboratory-based data and scanning imagery.

    Identification of Drugs Blocking SARS-CoV-2 Infection MESHD using Human Pluripotent Stem Cell-derived Colonic MESHD Organoids

    Authors: Xiaohua Duan; Yuling Han; Liuliu Yang; Benjamin Nilsson; Pengfei Wang; Tuo Zhang; Xing Wang; Dong Xu; Jenny Zhaoying Xiang; skyler uhl; Yaoxing Huang; Huanhuan Chen; Hui Wang; Benjamin R. tenOever; Robert E. Schwartz; David D Ho; Fong Cheng Pan; Shuibing Chen; Todd R. Evans

    doi:10.1101/2020.05.02.073320 Date: 2020-05-02 Source: bioRxiv

    Summary ParagraphThe current COVID-19 pandemic is caused by SARS-coronavirus MESHD 2 (SARS-CoV-2). There are currently no therapeutic options for mitigating this disease due to lack of a vaccine and limited knowledge of SARS-CoV-2 biology. As a result, there is an urgent need to create new disease models to study SARS-CoV-2 biology and to screen for therapeutics using human disease-relevant tissues. COVID-19 patients typically present with respiratory symptoms including cough HP, dyspnea HP dyspnea MESHD, and respiratory distress HP, but nearly 25% of patients have gastrointestinal indications including anorexia HP anorexia MESHD, diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Moreover, these symptoms are associated with worse COVID-19 outcomes1. Here, we report using human pluripotent stem cell-derived colonic MESHD organoids (hPSC-COs) to explore the permissiveness of colonic cell types to SARS-CoV-2 infection MESHD. Single cell RNA-seq and immunostaining showed that the putative viral entry receptor ACE2 is expressed in multiple hESC-derived colonic cell types, but highly enriched in enterocytes. Multiple cell types in the COs can be infected by a SARS-CoV-2 pseudo-entry virus, which was further validated in vivo using a humanized mouse model. We used hPSC-derived COs in a high throughput platform to screen 1280 FDA-approved drugs against viral infection MESHD. Mycophenolic acid and quinacrine dihydrochloride were found to block the infection of SARS-CoV-2 pseudo-entry virus in COs both in vitro and in vivo, and confirmed to block infection of SARS-CoV-2 MESHD virus. This study established both in vitro and in vivo organoid models to investigate infection of SARS-CoV-2 disease MESHD-relevant human colonic cell types and identified drugs that blocks SARS-CoV-2 infection MESHD, suitable for rapid clinical testing.

    Identification of Drugs Blocking SARS-CoV-2 Infection MESHD using Human Pluripotent Stem Cell-derived Colonic MESHD Organoids

    Authors: Xiaohua Duan; Yuling Han; Liuliu Yang; Benjamin E. Nilsson-Payant; Pengfei Wang; Tuo Zhang; Jenny Xiang; Dong Xu; Xing Wang; Skyler Uhl; Yaoxing Huang; Huanhuan Joyce Chen; Hui Wang; Benjamin tenOever; Robert E. Schwartz; David. D. Ho; Todd Evans; Fong Cheng Pan; Shuibing Chen

    doi:10.21203/rs.3.rs-24782/v1 Date: 2020-04-23 Source: ResearchSquare

    The current COVID-19 pandemic is caused by SARS-coronavirus MESHD 2 (SARS-CoV-2). There are currently no therapeutic options for mitigating this disease due to lack of a vaccine and limited knowledge of SARS-CoV-2 biology. As a result, there is an urgent need to create new disease models to study SARS-CoV-2 biology and to screen for therapeutics using human disease-relevant tissues. COVID-19 patients typically present with respiratory symptoms including cough HP, dyspnea HP dyspnea MESHD, and respiratory distress HP, but nearly 25% of patients have gastrointestinal indications including anorexia HP anorexia MESHD, diarrhea HP diarrhea MESHD, vomiting HP vomiting MESHD, and abdominal pain HP abdominal pain MESHD. Moreover, these symptoms are associated with worse COVID-19 outcomes1. Here, we report using human pluripotent stem cell-derived colonic MESHD organoids (hPSC-COs) to explore the permissiveness of colonic cell types to SARS-CoV-2 infection MESHD. Single cell RNA-seq and immunostaining showed that the putative viral entry receptor ACE2 is expressed in multiple hESC-derived colonic cell types, but highly enriched in enterocytes. Multiple cell types in the COs can be infected by a SARS-CoV-2 pseudo- entry virus, which was further validated in vivo using a humanized mouse model. We used hPSC-derived COs in a high throughput platform to screen 1280 FDA-approved drugs against viral infection MESHD. Mycophenolic acid and quinacrine dihydrochloride were found to block the infection of SARS-CoV-2 pseudo-entry virus in COs both in vitro and in vivo, and confirmed to block infection of SARS-CoV-2 MESHD virus. This study established both in vitro and in vivo organoid models to investigate infection of SARS-CoV-2 disease MESHD-relevant human colonic cell types and identified drugs that blocks SARS-CoV-2 infection MESHD, suitable for rapid clinical testing.

    Distinguish Coronavirus Disease MESHD 2019 Patients in General Surgery Emergency by CIAAD Scale: Development and Validation of a Prediction Model Based on 822 Cases in China

    Authors: Bangbo Zhao; Yingxin Wei; Wenwu Sun; Cheng Qin; Xingtong Zhou; Zihao Wang; Tianhao Li; Hongtao Cao; Weibin Wang; Yujun Wang

    doi:10.1101/2020.04.18.20071019 Date: 2020-04-23 Source: medRxiv

    IMPORTANCE In the epidemic, surgeons cannot distinguish infectious acute abdomen patients suspected COVID-19 quickly and effectively. OBJECTIVE To develop and validate a predication model, presented as nomogram and scale, to distinguish infectious acute abdomen patients suspected coronavirus disease MESHD 2019 (COVID-19). DESIGN Diagnostic model based on retrospective case series. SETTING Two hospitals in Wuhan and Beijing, China. PTRTICIPANTS 584 patients admitted to hospital with laboratory confirmed SARS-CoV-2 from 2 Jan 2020 to15 Feb 2020 and 238 infectious acute abdomen patients receiving emergency operation from 28 Feb 2019 to 3 Apr 2020. METHODS LASSO regression and multivariable logistic regression analysis were conducted to develop the prediction model in training cohort. The performance SERO of the nomogram was evaluated by calibration curves, receiver operating characteristic (ROC) curves, decision curve analysis (DCA) and clinical impact curves in training and validation cohort. A simplified screening scale and managing algorithm was generated according to the nomogram. RESULTS Six potential COVID-19 prediction variables were selected and the variable abdominal pain HP abdominal pain MESHD was excluded for overmuch weight. The five potential predictors, including fever HP fever MESHD, chest computed tomography (CT), leukocytes (white blood SERO cells, WBC), C-reactive protein (CRP) and procalcitonin (PCT), were all independent predictors in multivariable logistic regression analysis (p[≤]0.001) and the nomogram, named COVID-19 Infectious Acute Abdomen Distinguishment ( CIAAD MESHD) nomogram, was generated. The CIAAD nomogram showed good discrimination and calibration (C-index of 0.981 (95% CI, 0.963 to 0.999) and AUC of 0.970 (95% CI, 0.961 to 0.982)), which was validated in the validation cohort (C-index of 0.966 (95% CI, 0.960 to 0.972) and AUC of 0.966 (95% CI, 0.957 to 0.975)). Decision curve analysis revealed that the CIAAD nomogram was clinically useful. The nomogram was further simplified into the CIAAD scale. CONCLUSIONS We established an easy and effective screening model and scale for surgeons in emergency department to distinguish COVID-19 patients from infectious acute abdomen patients. The algorithm based on CIAAD scale will help surgeons manage infectious acute abdomen patients suspected COVID-19 more efficiently.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-23967/v1 Date: 2020-04-21 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 MESHD (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected MESHD patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever HP fever MESHD in 13 (65%) patients, cough HP in 9 (45%), headache HP headache MESHD in 3 (15%), fatigue HP fatigue MESHD in 6 (30%), diarrhea HP diarrhea MESHD in 3 (15%), and abdominal pain HP abdominal pain MESHD in 2 (10%). Six patients (30%) developed shortness of breath MESHD upon admission. The median time from exposure to onset of illness was 6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency. The dynamic changes in lymphocyte levels can predict disease status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.